An open-label, long term (52 week) extension study to evaluate the safety,tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 incombination with amlodipine in patients with essential hypertension

ovartis Farmacéutica, S.A.0 个研究点目标入组 600 人开始时间: 2013年11月12日最近更新: 2014年8月5日

试验速览

暂无简介。

•1. Written informed consent for the extension must be obtained before any assessment is performed.
•2. Patients who have successfully completed protocol CLCZ696A2320 and are able to safely continue into the open-label extension as judged by the investigator.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 476
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 124

•1. Patients who experienced a serious drug-related adverse event in study CLCZ696A2320.
•2. Patients who develop a condition during the core study that would have excluded them from participation in the core study.
•3. Patients with hypersensitivity to thiazide diuretics.

发起方

ovartis Farmacéutica, S.A.